Znn3bq.jpeg
²é¿´: 3238  |  »Ø¸´: 14
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


[½»Á÷] ÌåÍⰲȫÐÔÆÀ¼Û¡ª¡ªÒ»¸öÐÂÐ˵ÄÍâ°üÊг¡£¿ ÒÑÓÐ11È˲ÎÓë

Ò©Îï¶¾ÐÔ·ÖΪon-target¶¾ÐÔºÍoff-target¶¾ÐÔ£¬µ¥¿Ë¡¿¹ÌåµÄÑ¡ÔñÐԸߣ¬Ö÷ÒªÊÇon-target¶¾ÐÔ£¬ÕâÖÖ¶¾ÐÔ¿ÉÄÜÊǰÐ×éÖ¯exaggerated pharmacology£¬Ò²¿ÉÄÜÊǶԷǰÐ×éÖ¯µÄon-target pharmacologyµ¼Ö£¬¶øoff-target¶¾ÐÔÖ÷Òª±íÏÖÔÚС·Ö×Ó¼°Æä´úл²úÎïÖС£75%µÄÒ©Î︱×÷ÓÃÊÇdose-dependent£¬²¢ÇÒ¿ÉÒÔͨ¹ýpharmacology profilesÔ¤²â¡£

ÌåÍâSPP£¨in vitro safety pharmacology profiling£©ÊÇŵ»ª¿ÆÑ§¼ÒÔÚ2005ÄêÌá³öµÄ¸ÅÄËüµÄ¶¨ÒåÊÇÔÚÒ©ÎïÑз¢ÔçÆÚ£¨Ïȵ¼»¯ºÏÎïÑ¡ÔñºÍ½á¹¹ÓÅ»¯¹ý³ÌÖУ©£¬Í¨¹ý²âÊÔһϵÁÐoff-target£¬³õ²½Ô¤²âÒ©Î︱×÷Ó㬲¢Ö¸µ¼½á¹¹ÓÅ»¯£¬Ñ¡³ö°²È«ÐÔ×îºÃµÄ·Ö×Ó½øÈ붯ÎïʵÑé¡£ÌåÍâSPPµÄÖÕ¼«Ä¿µÄÊÇÌá¸ßÒ©ÎïÔÚ¶¯ÎïʵÑéºÍÁÙ´²µÄ³É¹¦ÂÊ¡£

ÌåÍâSPPµÄÓŵ㣺
1.³É±¾µÍ¡¢Ëٶȿ죻
2.ÔÚÏȵ¼»¯ºÏÎïÓÅ»¯µÄʱºò¾Í·¢ÏÖ¶¾ÐÔ£¬¿ÉÒÔÖ¸µ¼½á¹¹ÓÅ»¯£¬¶ø´«Í³µÄ°²È«ÐÔÆÀ¼ÛÒÀÀµ¶¯ÎïʵÑéºÍÁÙ´²Ñо¿£¬·Ö×ÓºóÆÚÑз¢Ê§°Ü£¬ºÜÄѻعýÍ·À´½øÐнṹÓÅ»¯£»
3.ÓÉÓÚ¶¯ÎïÓëÈËÌåµÄ²îÒ죬ijЩ¸±×÷ÓÃͨ¹ý¶¯ÎïʵÑéÊÇ·¢ÏÖ²»Á˵쬲»Èç5-HT2BÒýÆðµÄÐİêĤËðÉË£¬¶øÌåÍâSPPÓõÄÊÇÈËÌåµ°°×£¬¿ÉÒÔÔ¤²âÕâ·½ÃæµÄ¸±×÷Óá£

ÌåÍâSPPµÄǰÌáÓÐÁ½¸ö£º
µÚÒ»£¬È·Ö¤off-targetÓ븱×÷ÓõĹØÏµ£¬¶¾ÀíѧµÄ¶«Î÷£¬ËäÈ»ºÜÄÑ£¬ºÃÔÚÒ»µ©È·Ö¤£¬´ó¼Ò¶¼¿ÉÒÔÓá£
µÚ¶þ£¬ÈçºÎÑ¡Ôñoff-target¼¯£¬ÕâÈ¡¾öÓÚ¸÷ÆóÒµ×Ô¼ºµÄ³É±¾¡ª¡ªÐ§Òæ·ÖÎö¡£²âÊÔµÄoff-targetÔ½¶à£¬ÌåÍâSPPµÄ½á¹ûԽ׼ȷ£¬µ«»¨µÄÇ®×ÔȻԽ¶à¡£Ä³¸öoff-targetÊÇ·ñÐèÒª²âÊÔ£¬È¡¾öÓÚËüµÄhit rateºÍimpact£¬Åµ»ª²âÊÔÁË1832¸ö»¯ºÏÎÆäÖÐ980¸ö»¯ºÏÎï¶ÔhERGµÄIC50СÓÚ30¦ÌM£¬Õâ¾ÍÊǸßhit rateÁË£¬¶øhERGÒÖÖÆÒýÆðÐÄÂÉʧ³£ÉõÖÁËÀÍö£¬Õâ¾ÍÊǸßimpact£¬ËùÒÔhERG±ØÐëÑ¡Èëoff-target¼¯¡£¶øÄ³Ð©off-target±ÈÈçÍʺÚËØÊÜÌåMT3£¬¾¡¹Ühit rateÒ²´óÓÚ30%£¬ÓÉÓÚûÓÐÑÏÖØ¸±×÷Óã¬Òò´Ë¿ÉÒÔ²»¿¼ÂÇ¡£

ÌåÍâSPP¿ÉÒԷֽ׶νøÐУ¬Ç°ÆÚ»¯ºÏÎïÊýÁ¿¶à£¬¿ÉÒÔ²âÊÔÉÙÁ¿µÄoff-target£¬¶ø×¼±¸×ö¶¯ÎïʵÑ飬ֻʣÏÂÒ»¸öºòÑ¡·Ö×Ó£¬¾Í¿ÉÒÔÀ©´óoff-target¼¯¡£²âÊÔoff-targetÒ²ÊÇÓн²¾¿µÄ£¬¿ÉÒÔÖ»²âÒ»¸öŨ¶È£¨Ò»°ã10¦ÌM£©£¬¸ü׼ȷһµã¿ÉÒÔ²â¶à¸öŨ¶È£¬¼ÆËã¸÷×ÔµÄIC50Öµ¡£Åµ»ª·Ö½×¶Î½øÐÐÌåÍâSPP£º
primary panel (23 targets): lead chemical seriesµÄÑ¡Ôñ¡¢lead optimization¹ý³ÌÖеÄrapid check£»
second panel (70 targets): ÔÚ½øÈëpreclinical֮ǰ£¬½øÒ»²½characterize the candidate£»
third panel (85 additional targets): fullÑ¡ÔñÐÔÆÀ¼Û¡£

²âÊÔoff-target»îÐԺ󣬾ͿÉÒÔ×÷promiscuity·ÖÎö£¬IC<10¦ÌMµÄËã×÷ÃüÖУ¬ÃüÖеÄoff-target³ýÒÔ×ܵÄoff-targetÊý¾ÍµÃ³öpromiscuityÖµ£¬promiscuityÖµÔ½´ó£¬·Ö×Ó°²È«ÐÔÔ½µÍ£¬promiscuityÖµ´óÓÚ20%¾ÍÊǸßΣÁË£¬ÊÇ·ñ½øÈ붯ÎïʵÑé¾ÍÐèÒªÉ÷ÖØ¿¼ÂÇ¡£°´Åµ»ªµÄͳ¼ÆÊý¾Ý£¬ÁÙ´²Ê§°ÜºÍÉÏÊк󳷻صÄÒ©ÎïÖУ¬promiscuityÖµÔÚ20%ÒÔÉϵÄÕ¼1/5ÒÔÉÏ£¬¶ø³É¹¦µÄÒ©ÎïÖУ¬promiscuityÖµÔÚ20%ÒÔÉϵÄÖ»Õ¼1/20¡£

promiscuityÖµ²»ÊÇÒ»¸ö¾ø¶ÔµÄ¸ÅÄÒòΪÿ¸öoff-targetµÄÓ°ÏìÁ¦²»Í¬£¬Èç¹ûÒ»¸ö·Ö×Ó¶ÔhERGÓÐÒÖÖÆ»îÐÔ£¬¼´±ãûÓÐÃüÖÐÆäËûµÄoff-target£¬Ò²ÊDz»ÄܽøÈëÁÙ´²µÄ¡£Í¬Ê±²»Í¬Ò©Îï¶Ô¸±×÷ÓõÄÒªÇó²»Ò»Ñù£¬ÍíÆÚ°©Ö¢Ò©Îï¿ÉÒÔ¶Ô¸±×÷ÓÃ·Å¿í£¬¶øÄ³Ð©ÐèÒª³¤ÆÚÓÃÒ©µÄ·ÇÖÂËÀÐÔ¼²²¡ÔòÒªÑϸñ¿ØÖƸ±×÷Ó㬶ÔÌåÍâSPPÆÀ¼Û½á¹ûµÄ·ÖÎö¿¿Ñо¿Õß×Ô¼º¡£

ÓÉÓÚÒÖÖÆhERG£¬±»ÕٻصÄÒ©ÎïÓУºTerodiline (IC50=450nM); Terfenadine (IC50=204nM); Sertindole (IC50=3nM); Astemizole (IC50=0.9nM); Grepafloxacin (IC50=50¦ÌM); Levomethadyl acetate (IC50=3¦ÌM); Cisapride (IC50=15nM); Droperidol (IC50=32nM)¡£FDAÒªÇóÁÙ´²Ñо¿Ç°²â¶¨hERG»îÐÔ£¬±ÜÃâÐÄÂÉʧ³£¸±·´Ó¦¡£

²Î¿¼ÎÄÏ×£º
Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, Whitebread S. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012, 11, 909-922.
Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 2005, 10, 1421-1433.
Hamon J, Whitebread S, Techer-Etienne V, Le Coq H, Azzaoui K, Urban L. In vitro safety pharmacology profiling: what else beyond hERG? Future Med Chem. 2009, 1, 645-665.
Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012, 11, 751-761.

[ Last edited by ³ÕÃÎäìÏæ on 2012-12-11 at 10:23 ]
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

niebiao2008

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

study

ȷʵÌåÍâÆÀ¼ÛÒѾ­Ô½À´Ô½Êܵ½ÖØÊÓÁË£¬¶øÇÒǰÆÚ·¢ÏÖÎÊÌâ¿ÉÒÔ´ó´ó½µµÍºóÐø¿ª·¢µÄ·çÏÕ
²»¶Ïѧϰ,²»¶Ï½ø²½!
4Â¥2012-12-11 15:46:04
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 15 ¸ö»Ø´ð

yzshua1987

½ð³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ʲôÊÇon-target¶¾ÐÔºÍoff-target¶¾ÐÔÄØ£¿
ÎҺܱ¿¡£¡£¡£¡£¡£¡£¡£¡£µ«ÊÇÎÒÔ¸Òâ±£³ÖÎÒµÄÎïÖÖÌØÒìÐÔ£¡
5Â¥2012-12-11 19:33:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

marktiger

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÒýÓûØÌû:
5Â¥: Originally posted by yzshua1987 at 2012-12-11 19:33:17
ʲôÊÇon-target¶¾ÐÔºÍoff-target¶¾ÐÔÄØ£¿

×÷ÓÃÔڰеãÆ÷¹ÙµÄ¶¾ÐԺͰеãÆ÷¹ÙÖ®ÍâµÄ¶¾ÐÔ£¿
marktigerchen
6Â¥2012-12-12 08:45:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


¡ï
marktiger: ½ð±Ò+1, лл·ÖÏí 2012-12-13 08:35:38
ÒýÓûØÌû:
5Â¥: Originally posted by yzshua1987 at 2012-12-11 19:33:17
ʲôÊÇon-target¶¾ÐÔºÍoff-target¶¾ÐÔÄØ£¿

Ò©Îï·Ö×ÓÒ»°ã×÷ÓÃÓÚij¸ötarget¶ø²úÉú×÷Óã¬Õâ¸ötarget¿ÉÄÜÊÇÊÜÌ塢ø¡¢Àë×ÓͨµÀ£¬on-target¶¾ÐÔÊÇ×÷ÓÃÁ˶ԵÄtarget£¬µ«ÈÔÈ»²úÉúÁ˶¾ÐÔ£¬±ÈÈçij¸ötargetÔÚÈ«Éí¶¼Óзֲ¼£¬¶øÒªÖÎÁƵIJ¡È´ÊÇij¸öÆ÷¹Ù¾Ö²¿£¬Õâʱ¾Í»áÓÐon-target¶¾ÐÔ£¬µ±È»Ò²ÓпÉÄÜÊǹý¶È×÷ÓÃÒýÆðÁË£¬±ÈÈ罵ѪÌÇÒ©£¬µ±ÑªÌǻعéÕý³£ºó£¬Ò©ÎïÈÔÈ»·¢»Ó×÷Ó㬾ͻá²úÉúµÍѪÌǸ±×÷Óá£off-target¶¾ÐÔÊÇÖ¸×÷Óõ½ÁËÖÎÁÆÒÔÍâµÄtarget¶ø²úÉú¶¾ÐÔ£¬±ÈÈçij¸ö¿¹¾«Éñ²¡Ò©ÓÐÐÄÂÉʧ³£µÄ¸±×÷Óã¬ÄÇôÕâ¸öÒ©¿ÉÄܼÈ×÷Óõ½¿¹¾«Éñ²¡µÄtarget£¬Í¬Ê±»¹×÷Óõ½Á˼ØÀë×ÓͨµÀhERG£¬ÒýÆðÐÄÂÉʧ³£¡£
7Â¥2012-12-12 09:09:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] µ÷¼Á +25 ²»·ê´º 2026-04-07 26/1300 2026-04-12 11:53 by ´óÁ¦Ë®ÊÖÁ¦´óÎÞÇ
[¿¼ÑÐ] µçÆø¹¤³Ìר˶320Çóµ÷¼Á +5 СÂé×Ó111 2026-04-10 5/250 2026-04-12 10:47 by zhouyuwinner
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸²ÄÁÏ¿ÆÑ§Ó빤³Ì985£¬365·Ö£¬ +8 ²Ä»¯Àî¿É 2026-04-11 10/500 2026-04-12 08:42 by 852137818
[¿¼ÑÐ] Çóµ÷¼Á£¬262»úеר˶ +8 àÅyyl 2026-04-08 8/400 2026-04-12 02:31 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤300Çóµ÷¼Á +39 Ф¿ªÎÄ 2026-04-09 43/2150 2026-04-12 01:30 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] Çóµ÷¼Á +6 СÄô°®Ñ§Ï° 2026-04-11 9/450 2026-04-11 21:20 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005 +18 ioodiiij 2026-04-08 18/900 2026-04-11 20:25 by liyun12321
[¿¼ÑÐ] Çóµ÷¼Á +3 θ¾·ÂÎÀÛÁË 2026-04-11 5/250 2026-04-11 14:13 by luhong1990
[¿¼ÑÐ] 298Çóµ÷¼Á +5 ²ÐºÉÐÂÁø 2026-04-07 5/250 2026-04-11 11:02 by ×ÏêØ×ÏÆå
[¿¼ÑÐ] 085500Çóµ÷¼Á²ÄÁÏ +10 Ò×11122 2026-04-09 10/500 2026-04-11 10:39 by maddjdld
[¿¼ÑÐ] 301Çóµ÷¼Á +5 149. 2026-04-10 5/250 2026-04-10 15:45 by ²ñС°×
[¿¼ÑÐ] Ò»Ö¾Ô¸»¦9£¬326ÉúÎïѧÇóÏà¹Ø×¨Òµµ÷¼Á +4 Áõīī 2026-04-09 4/200 2026-04-10 12:07 by pengliang8036
[¿¼ÑÐ] Çóµ÷¼Á ²ÄÁÏÓ빤³Ì 324·Ö ר˶ +19 ôæôæÒ»ÊéÉú 2026-04-10 21/1050 2026-04-10 11:41 by wp06
[¿¼ÑÐ] Çൺ¿Æ¼¼´óѧ²ÄÁÏѧԺ£¬»·¾³Ñ§Ôºµ÷¼Á²¹Â¼4ÔÂ10ÈÕÒÔǰ¶¼¿ÉÒÔ +3 1Çà¿Æ´ó¡£ 2026-04-09 5/250 2026-04-10 09:58 by ôæôæÒ»ÊéÉú
[¿¼ÑÐ] ²ÄÁÏר˶³õÊÔ·Ö332Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ£¬ +12 ¹ÊÈË?? 2026-04-09 12/600 2026-04-09 18:34 by Ccclqqq
[¿¼ÑÐ] Ò»Ö¾Ô¸ÎäÀí³µÁ¾ 281 Çóµ÷¼Á +5 Éϰ¶Ñо¿Éú. 2026-04-07 5/250 2026-04-09 15:56 by onlyÖÜ
[¿¼ÑÐ] 270Çóµ÷¼Á +3 031127 2026-04-06 4/200 2026-04-08 21:00 by ÄæË®³Ë·ç
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ª´ó»¯Ñ§327Çóµ÷¼Á +12 ÍõÍõ°×ʯ 2026-04-06 13/650 2026-04-08 16:05 by luoyongfeng
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +13 ºº123456 2026-04-07 14/700 2026-04-07 22:53 by À´¿´Á÷ÐÇÓê10
[¿¼ÑÐ] 362Çóµ÷¼ÁÒ»Ö¾Ô¸ÖйúʯÓÍ´óѧ +4 ÎÒÒª¿¼´ó 2026-04-06 6/300 2026-04-06 14:11 by Î޼ʵIJÝÔ­
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û